US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

AdvisorShares Psychedelics ETF

24.87

-0.2800-1.11%

Post-market: 24.870.00000.00%19:30 EDT

Volume:23.02K

Turnover:576.09K

Market Cap:57.70M

PE:- -

High:25.58

Open:25.53

Low:24.67

Close:25.15

52wk High:27.02

52wk Low:15.63

Shares:2.32M

Float Shares:2.32M

Volume Ratio:0.72

T/O Rate:0.99%

Dividend:1.71

Dividend Rate:6.86%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Talisman Mining Raises A$4 Million to Fast-Track Gold Exploration and Growth

Alkermes EVP R&D, Chief Medical Officer Craig C. Hopkinson Disposes of 9,000 Shares for $422,874

Upstream Bio Announces Pivotal Phase 3 Development Plans for Verekitug in Both Severe Asthma and CRSwNP

Compass Pathways to Join Cantor Global Healthcare Conference Fireside Chat

Dipietro Group Completes IPO Greenshoe, Raises €2.1 Million

Alvo Minerals shareholders back prior capital raisings at general meeting

AbbVie Targets Rare Blood Disorder With New Phase 3 Etentamig Trial Plan

BioNTech Stock (BNTX) Is Tumbling on Friday – Here’s Why

Unusually active option classes on open August 26th

COMPASS Pathways (CMPS) Nears FDA Filing for COMP360 Following a Valuation Question

Simply Wall St.

Nxera to Book US$10m Milestone as FDA Clears Phase 2 Alzheimer’s Drug

FireFly announces successful A$190m capital raising to fund development and resource growth

NRX Pharmaceuticals Price Target Maintained with a $45.00/Share by HC Wainwright & Co.

Baiyunshan Pharmaceutical Subsidiary Gets Supplementary Drug Approval for Low Blood Pressure Injection

MT Newswires Live

Alkermes’ Alixorexton Posts Positive Phase 2 Vibrance-1 Results in Narcolepsy Type 1 Study

The Lancet Neurology Publishes Data from Alkermes’ Positive Vibrance-1 Phase 2 Study of Alixorexton in Adults with Narcolepsy Type 1

THOMSON REUTERS

Savara announces presentations of Results from Phase 3 trial of Molgramostim

Amgen Extends MariTide Study In Obesity And Diabetes, Keeping Investor Focus On Long-Term Potential

Biogen Expands Autoimmune Pipeline With New Graves’ Disease Trial

AbbVie’s Emraclidine Schizophrenia Study Ends Early: What Investors Need to Know Now

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigerfiesta.com/stock/PSIL/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PSIL","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PSIL\",,,,,undefined,":{"symbol":"PSIL","market":"US","secType":"STK","nameCN":"AdvisorShares Psychedelics ETF","latestPrice":24.87,"timestamp":1789761600000,"preClose":25.15,"halted":0,"volume":23017,"hourTrading":{"tag":"盘后","latestPrice":24.87,"preClose":24.87,"latestTime":"19:30 EDT","volume":13,"amount":323.31,"timestamp":1789774204499,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.011133200795228533,"floatShares":2319976,"shares":2319976,"eps":0,"marketStatus":"Market Closed","change":-0.28,"latestTime":"09-18 16:00:00 EDT","open":25.53,"high":25.58,"low":24.67,"amount":576091.019912,"amplitude":0.036183,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1789977600000},"marketStatusCode":7,"adr":0,"exchange":"ARCA","adjPreClose":25.15,"sharesOutstanding":1184976,"nav":24.676,"aum":57248825.63,"dividendRate":0.068565,"bidAskSpread":0,"preHourTrading":{"tag":"盘前","latestPrice":25.86,"preClose":25.15,"latestTime":"09:17 EDT","volume":28,"amount":719.9700200000001,"timestamp":1789737431335,"change":0.71,"changeRate":0.028231,"amplitude":0.020278},"postHourTrading":{"tag":"盘后","latestPrice":24.87,"preClose":24.87,"latestTime":"19:30 EDT","volume":13,"amount":323.31,"timestamp":1789774204499,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.7196050720575493,"impliedVol":0.3416,"impliedVolPercentile":0.4661},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PSIL\",,,,,undefined,":{"symbol":"PSIL","floatShares":2319976,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.7196050720575493,"shares":2319976,"dividePrice":1.7052,"high":25.58,"amplitude":0.036183,"preClose":25.15,"low":24.67,"week52Low":15.6348,"pbRate":"--","week52High":27.0175,"institutionHeld":0,"latestPrice":24.87,"eps":0,"divideRate":0.068565,"volume":23017,"delay":0,"ttmEps":0,"open":25.53,"prevYearClose":17.17,"prevWeekClose":24.7682,"prevMonthClose":24.62,"prevQuarterClose":24.05,"fiveDayClose":24.7682,"twentyDayClose":25.95,"sixtyDayClose":21.7221},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PSIL\",params:#limit:5,,,undefined,":[{"date":"2025-12-22","symbol":"PSIL","amount":1.68387,"announcedDate":"2025-12-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-22","defaultRemindTime":1766413800000,"name":"AdvisorShares Psychedelics ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-29","payableDate":"2025-12-22","currency":"USD","dateTimestamp":1766379600000,"payDate":"2025-12-29"},{"date":"2025-09-22","symbol":"PSIL","amount":0.02007,"announcedDate":"2025-09-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-22","defaultRemindTime":1758547800000,"name":"AdvisorShares Psychedelics ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-29","payableDate":"2025-09-22","currency":"USD","dateTimestamp":1758513600000,"payDate":"2025-09-29"},{"date":"2025-06-23","symbol":"PSIL","amount":0.01191,"announcedDate":"2025-06-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-23","defaultRemindTime":1750685400000,"name":"AdvisorShares Psychedelics ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-06-27","payableDate":"2025-06-23","currency":"USD","dateTimestamp":1750651200000,"payDate":"2025-06-27"},{"date":"2025-03-21","symbol":"PSIL","amount":0.16343,"announcedDate":"2025-03-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-21","defaultRemindTime":1742563800000,"name":"AdvisorShares Psychedelics ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-03-28","payableDate":"2025-03-21","currency":"USD","dateTimestamp":1742529600000,"payDate":"2025-03-28"},{"date":"2024-12-23","symbol":"PSIL","amount":0.05477,"announcedDate":"2024-12-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-23","defaultRemindTime":1734964200000,"name":"AdvisorShares Psychedelics ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-30","payableDate":"2024-12-23","currency":"USD","dateTimestamp":1734930000000,"payDate":"2024-12-30"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PSIL\",market:\"US\",,,undefined,":[{"executeDate":"2022-09-26","recordDate":"2022-09-27","paymentDate":"2022-09-30","value":0.05421,"currency":"USD"},{"executeDate":"2023-09-25","recordDate":"2023-09-26","paymentDate":"2023-09-29","value":0.00336,"currency":"USD"},{"executeDate":"2024-09-23","recordDate":"2024-09-23","paymentDate":"2024-09-30","value":0.1087,"currency":"USD"},{"executeDate":"2024-12-23","recordDate":"2024-12-23","paymentDate":"2024-12-30","value":0.05477,"currency":"USD"},{"executeDate":"2025-03-21","recordDate":"2025-03-21","paymentDate":"2025-03-28","value":0.16343,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PSIL\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PSIL\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2664862521","title":"Talisman Mining Raises A$4 Million to Fast-Track Gold Exploration and Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2664862521","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664862521?lang=en_us&edition=fundamental","pubTime":"2026-09-02 07:44","pubTimestamp":1788306290,"startTime":"0","endTime":"0","summary":"Talisman Mining Limited ( ($AU:TLM) ) has issued an update. Talisman Mining Limited has launched its first capital raising in over a decade, securi...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/talisman-mining-raises-a4-million-to-fast-track-gold-exploration-and-growth?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/talisman-mining-raises-a4-million-to-fast-track-gold-exploration-and-growth?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PSIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664864142","title":"Alkermes EVP R&D, Chief Medical Officer Craig C. Hopkinson Disposes of 9,000 Shares for $422,874","url":"https://stock-news.laohu8.com/highlight/detail?id=2664864142","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664864142?lang=en_us&edition=fundamental","pubTime":"2026-09-02 07:09","pubTimestamp":1788304180,"startTime":"0","endTime":"0","summary":"Alkermes EVP R&D, Chief Medical Officer Craig C. Hopkinson disposes of 9,000 shares for $422,874Craig C. Hopkinson, EVP R&D, Chief Medical Officer, sold 9,000 ordinary shares on Sep. 1 at USD 46.99.He","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260901:nNDLgbNz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Alkermes EVP R&D, Chief Medical Officer Craig C. Hopkinson Disposes of 9,000 Shares for $422,874","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MEDX","FBT","IBRN","BK4139","PSIL","PSCH","ALKS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664855897","title":"Upstream Bio Announces Pivotal Phase 3 Development Plans for Verekitug in Both Severe Asthma and CRSwNP","url":"https://stock-news.laohu8.com/highlight/detail?id=2664855897","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664855897?lang=en_us&edition=fundamental","pubTime":"2026-09-01 19:00","pubTimestamp":1788260400,"startTime":"0","endTime":"0","summary":"– Following productive FDA discussions, Upstream Bio will study 400 mg of verekitug administered every 12 weeks, versus placebo, in severe asthma and CRSwNP with one pivotal Phase 3 trial in each indi","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/01/3353967/0/en/upstream-bio-announces-pivotal-phase-3-development-plans-for-verekitug-in-both-severe-asthma-and-crswnp.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TSLI","09366","TEST","TSLW","07366","TSLS","TLA","LABU","TSLO","09766","TSLQ","PSIL","07766","TSLL","TESC","TSLR","TSLG","TSLY","TSLT","TSYY","TESL","ELOL","TSLZ","TSDD","TSL","CRSH","TSII","TSLP","BBC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664858428","title":"Compass Pathways to Join Cantor Global Healthcare Conference Fireside Chat","url":"https://stock-news.laohu8.com/highlight/detail?id=2664858428","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664858428?lang=en_us&edition=fundamental","pubTime":"2026-09-01 18:30","pubTimestamp":1788258620,"startTime":"0","endTime":"0","summary":"Compass Pathways to join Cantor Global Healthcare Conference fireside chatCompass Pathways will attend the 2026 Cantor Global Healthcare Conference on Sept. 9, 2026.Management is scheduled for a fireside chat at 3:20 p.m. ET.A panel session, “PSYCH! Accessing The New Wave of Psychedelics,” is set for 4:30 p.m. ET.Disclaimer:This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Compass Pathways plc published the original content used to generate this news brief via Business Wire  on September 01, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260901:nNDL9r5Tyx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PSIL","CMPS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663076208","title":"Dipietro Group Completes IPO Greenshoe, Raises €2.1 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2663076208","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663076208?lang=en_us&edition=fundamental","pubTime":"2026-08-31 17:16","pubTimestamp":1788167805,"startTime":"0","endTime":"0","summary":"The latest announcement is out from Dipietro Group S.P.A ( ($IT:DPG) ). Dipietro Group S.p.A. has completed its IPO-related capital raising with th...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/dipietro-group-completes-ipo-greenshoe-raises-e2-1-million?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/dipietro-group-completes-ipo-greenshoe-raises-e2-1-million?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4127","REDS","PSIL","VGT","BK4585","BK4588","KCE","IPOS","IPO","FRHC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663026000","title":"Alvo Minerals shareholders back prior capital raisings at general meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2663026000","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663026000?lang=en_us&edition=fundamental","pubTime":"2026-08-31 10:38","pubTimestamp":1788143921,"startTime":"0","endTime":"0","summary":"An update from Alvo Minerals Limited ( ($AU:ALV) ) is now available. Alvo Minerals has confirmed that shareholders at its 31 August general meeting...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/alvo-minerals-shareholders-back-prior-capital-raisings-at-general-meeting?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/alvo-minerals-shareholders-back-prior-capital-raisings-at-general-meeting?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PSIL","MTX","BK4109"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663009747","title":"AbbVie Targets Rare Blood Disorder With New Phase 3 Etentamig Trial Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2663009747","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663009747?lang=en_us&edition=fundamental","pubTime":"2026-08-29 00:31","pubTimestamp":1787934678,"startTime":"0","endTime":"0","summary":"Abbvie ($ABBV) announced an update on their ongoing clinical study. AbbVie (ABBV) has posted a new Phase 3 trial plan for its drug etentamig in amy...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/abbvie-targets-rare-blood-disorder-with-new-phase-3-etentamig-trial-plan?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/abbvie-targets-rare-blood-disorder-with-new-phase-3-etentamig-trial-plan?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0320765646.SGD","AGNG","LU1496350171.SGD","LU1934455194.USD","GLAM","LU0942090050.USD","RXL","VHT","SG9999011175.SGD","IE00BLSP4239.USD","IE000SO60NU8.SGD","MEDX","LU1267930490.SGD","ABBV","PSIL","IE000BZT7R73.USD","BK4585","LU0985320562.USD","FTXH","PPH","TRUH","IE0000B7K699.USD","LU1244550494.USD","IE00B2B36J28.USD","LU1989772840.SGD","FHLC","LU0029864427.USD","LU0057025933.USD","XLV","LU2129689431.USD","LU2089283258.USD","LU0868494708.USD","LU1670627923.USD","IYH","IXJ","PJP","LU1496350502.SGD","BBC","BK4550","IE0002141913.USD","JDOC","LU1074936037.SGD","IE00BBT3K403.USD","IE00BSNM7G36.USD","LU0726765562.USD","LU2112291526.USD","IE00B42XCP33.USD","IE0004445239.USD","LU0795875169.SGD","LU2237443465.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663547097","title":"BioNTech Stock (BNTX) Is Tumbling on Friday – Here’s Why","url":"https://stock-news.laohu8.com/highlight/detail?id=2663547097","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663547097?lang=en_us&edition=fundamental","pubTime":"2026-08-29 00:15","pubTimestamp":1787933700,"startTime":"0","endTime":"0","summary":"BioNTech ($BNTX) shares declined as much as 10% on Friday after the company said it has ended a key Phase 2 trial for its mRNA colorectal cancer va...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/biontech-stock-bntx-is-tumbling-on-friday-heres-why?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/biontech-stock-bntx-is-tumbling-on-friday-heres-why?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PSIL","BBC","BK4568","BK4551","BK4585","BNTX","BK4535","BK4139","BK4588","BK4548"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662995717","title":"Unusually active option classes on open August 26th","url":"https://stock-news.laohu8.com/highlight/detail?id=2662995717","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662995717?lang=en_us&edition=fundamental","pubTime":"2026-08-26 21:40","pubTimestamp":1787751623,"startTime":"0","endTime":"0","summary":"Unusual total active option classes on open include: COMPASS Pathways PLC (CMPS), Burlington Stores (BURL), Rackspace Technology (RXT), UP Fintech ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/unusually-active-option-classes-on-open-august-26th-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/unusually-active-option-classes-on-open-august-26th-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["UP","FTVI","LU1878469433.USD","BK4008","BURL","BK4094","LU0077335932.USD","PSIL","BK4139","BK4566","RXT","CMPS","LU0205194284.USD","BK4116","BK4608","LU0205193047.USD","LU2108987350.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662113637","title":"COMPASS Pathways (CMPS) Nears FDA Filing for COMP360 Following a Valuation Question","url":"https://stock-news.laohu8.com/highlight/detail?id=2662113637","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662113637?lang=en_us&edition=fundamental","pubTime":"2026-08-26 19:26","pubTimestamp":1787743564,"startTime":"0","endTime":"0","summary":"COMPASS Pathways (NasdaqGS:CMPS) is back in focus as investors watch the final stages of its planned FDA application for COMP360, a synthetic psilocybin treatment for people with treatment-resistant depression.\nOver the past year, COMPASS Pathways has seen strong momentum, with a year to date share price return of 127.18% and a 1 year total shareholder return of 212.61%. The recent 32.15% 30 day share price return suggests that enthusiasm around the FDA submission is building further.\nScan...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cmps/compass-pathways/news/compass-pathways-cmps-nears-fda-filing-for-comp360-following","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cmps/compass-pathways/news/compass-pathways-cmps-nears-fda-filing-for-comp360-following","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4588","LABU","BK4139","PSIL","BK4585","CMPS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662795913","title":"Nxera to Book US$10m Milestone as FDA Clears Phase 2 Alzheimer’s Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2662795913","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662795913?lang=en_us&edition=fundamental","pubTime":"2026-08-26 15:52","pubTimestamp":1787730745,"startTime":"0","endTime":"0","summary":"Sosei Group ( ($JP:4565) ) has provided an update. Nxera Pharma’s partner Neurocrine Biosciences has secured FDA IND acceptance for a Phase 2 trial...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/nxera-to-book-us10m-milestone-as-fda-clears-phase-2-alzheimers-drug?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/nxera-to-book-us10m-milestone-as-fda-clears-phase-2-alzheimers-drug?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","PSIL","BBC","LABU","IND","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662067764","title":"FireFly announces successful A$190m capital raising to fund development and resource growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2662067764","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662067764?lang=en_us&edition=fundamental","pubTime":"2026-08-26 11:53","pubTimestamp":1787716380,"startTime":"0","endTime":"0","summary":"Proceeds will be used for early works, long-lead items and resource drilling FireFly has received firm commitments to raise ~A$180m (before costs) via an Australian institutional placement and Canadia","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/26/3351065/0/en/firefly-announces-successful-a-190m-capital-raising-to-fund-development-and-resource-growth.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4173","BK4207","LIFE","UYM","XME","PSIL","DBB","BK4139","BK4563","BK4535","PICK","BMO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662560967","title":"NRX Pharmaceuticals Price Target Maintained with a $45.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2662560967","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662560967?lang=en_us&edition=fundamental","pubTime":"2026-08-26 00:58","pubTimestamp":1787677080,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NRXP/analyst-ratings","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PSIL","BK4007","NRXP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662078059","title":"Baiyunshan Pharmaceutical Subsidiary Gets Supplementary Drug Approval for Low Blood Pressure Injection","url":"https://stock-news.laohu8.com/highlight/detail?id=2662078059","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662078059?lang=en_us&edition=fundamental","pubTime":"2026-08-25 17:18","pubTimestamp":1787649510,"startTime":"0","endTime":"0","summary":"Guangzhou Baiyunshan Pharmaceutical Holdings  subsidiary Guangzhou Baiyunshan Mingxing Pharmaceutical received supplementary drug approval from China's National Medical Products Administration for its norepinephrine bitartrate injection.The drug approval covers drug prescription and manufacturing processes, registration, packaging materials, and revision of drug instructions.The drug is indicated for low blood pressure control.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0188","BK0070","PSIL","TBXU","BK0196","BK0175","BK0012","BK0028","BK0183","600332","BK0097","BK0239","BK0096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662620199","title":"Alkermes’ Alixorexton Posts Positive Phase 2 Vibrance-1 Results in Narcolepsy Type 1 Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2662620199","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662620199?lang=en_us&edition=fundamental","pubTime":"2026-08-25 06:30","pubTimestamp":1787610625,"startTime":"0","endTime":"0","summary":"Alkermes’ alixorexton posts positive Phase 2 Vibrance-1 results in narcolepsy type 1 studyAlkermes reported publication of positive Phase 2 Vibrance-1 results for alixorexton in adults with narcolepsy type 1 in The Lancet Neurology.Results were previously announced, not newly presented, showing improved daytime wakefulness and sleepiness measures versus placebo.Study also indicated reduced cataplexy at one dose, with broader patient-reported benefits in daily functioning.Safety profile appeared generally well tolerated, with mostly mild-to-moderate adverse events and no serious treatment-emergent events reported.Positive Phase 2 readouts supported the launch of the global Phase 3 Brilliance program testing once-daily and split-dose regimens in narcolepsy types 1 and 2.Disclaimer:This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purpos","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260824:nNDL56tjq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FBT","PSIL","IBRN","BK4139","MEDX","ALKS","PSCH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662201993","title":"The Lancet Neurology Publishes Data from Alkermes’ Positive Vibrance-1 Phase 2 Study of Alixorexton in Adults with Narcolepsy Type 1","url":"https://stock-news.laohu8.com/highlight/detail?id=2662201993","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662201993?lang=en_us&edition=fundamental","pubTime":"2026-08-25 06:30","pubTimestamp":1787610600,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260824:nTUA7VQ936:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MEDX","IBRN","PSCH","ALKS","FBT","PSIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662206573","title":"Savara  announces presentations of Results from Phase 3 trial of Molgramostim","url":"https://stock-news.laohu8.com/highlight/detail?id=2662206573","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662206573?lang=en_us&edition=fundamental","pubTime":"2026-08-25 04:10","pubTimestamp":1787602218,"startTime":"0","endTime":"0","summary":"Savara (SVRA) announced the acceptance of one oral presentation and two poster presentations on data from the Phase 3 IMPALA-2 clinical trial at th...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/savara-announces-presentations-of-results-from-phase-3-trial-of-molgramostim-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/savara-announces-presentations-of-results-from-phase-3-trial-of-molgramostim-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BBC","HYLG","SVRA","BK4139","GDOC","PSIL","MEDX","IDNA","NVIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662729270","title":"Amgen Extends MariTide Study In Obesity And Diabetes, Keeping Investor Focus On Long-Term Potential","url":"https://stock-news.laohu8.com/highlight/detail?id=2662729270","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662729270?lang=en_us&edition=fundamental","pubTime":"2026-08-25 00:31","pubTimestamp":1787589063,"startTime":"0","endTime":"0","summary":"Amgen Inc ($AMGN) announced an update on their ongoing clinical study. Amgen Inc. is moving ahead with MARITIME-2-EXTENSION, a Phase 3 trial that t...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/amgen-extends-maritide-study-in-obesity-and-diabetes-keeping-investor-focus-on-long-term-potential?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/amgen-extends-maritide-study-in-obesity-and-diabetes-keeping-investor-focus-on-long-term-potential?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00BJT1NW94.SGD","BK4139","IE0002141913.USD","AMGN","IE0009355771.USD","LU2089984988.USD","LU1061106388.HKD","TBXU","BK4534","BK4599","LU1983299246.USD","LU0058720904.USD","IBB","LU0289739699.SGD","IE00B4R5TH58.HKD","BK4585","IBBQ","PBE","LU2112291526.USD","SG9999001440.SGD","IE00BJJMRZ35.SGD","LU1057294990.SGD","BBC","BK4533","PJP","BK4566","LU1571399168.USD","PSIL","BK4581","LU0868494617.USD","LU2242652126.USD","BIB","LU0109394709.USD","LU1023059063.AUD","LU2242646821.SGD","BBH","BK4588","IE00BFTCPJ56.SGD","LU2468319806.SGD","IE00B2B36J28.USD","LU0320765992.SGD","LU0889565916.HKD","LU0122379950.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661294871","title":"Biogen Expands Autoimmune Pipeline With New Graves’ Disease Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2661294871","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661294871?lang=en_us&edition=fundamental","pubTime":"2026-08-22 00:33","pubTimestamp":1787330033,"startTime":"0","endTime":"0","summary":"Biogen Inc. ($BIIB) announced an update on their ongoing clinical study. Biogen Inc. has launched a Phase 2 trial testing felzartamab in adults wit...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/biogen-expands-autoimmune-pipeline-with-new-graves-disease-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/biogen-expands-autoimmune-pipeline-with-new-graves-disease-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","LU0889565916.HKD","BK4532","IE00B894F039.SGD","BK4139","IE00B19Z9Z06.USD","PBE","PSIL","BK4588","BMED","LU0234570918.USD","LU0320765992.SGD","BK4533","BBC","LU0109394709.USD","IE00B19Z9P08.USD","BIIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661294820","title":"AbbVie’s Emraclidine Schizophrenia Study Ends Early: What Investors Need to Know Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2661294820","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661294820?lang=en_us&edition=fundamental","pubTime":"2026-08-22 00:30","pubTimestamp":1787329825,"startTime":"0","endTime":"0","summary":"Abbvie ($ABBV) announced an update on their ongoing clinical study. AbbVie’s long-term Phase 2 trial NCT05443724, titled “A 52-week, Phase 2, Open-...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/abbvies-emraclidine-schizophrenia-study-ends-early-what-investors-need-to-know-now?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/abbvies-emraclidine-schizophrenia-study-ends-early-what-investors-need-to-know-now?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["JDOC","BK4588","PPH","LU0029864427.USD","LU1267930490.SGD","XLV","ISBC","LU0943347566.SGD","SG9999003800.SGD","IE00B4R5TH58.HKD","SG9999001440.SGD","IE000F7OJYX1.SGD","LU0158827948.USD","LU0432979614.USD","TRUH","LU1093756168.USD","LU2023251221.USD","FHLC","PJP","LU0256863811.USD","FTXH","GLAM","IE00BN8TJ469.HKD","LU1989772840.SGD","LU1003077747.HKD","IXJ","ABBV","LU1929549753.HKD","LU1934455863.HKD","IYH","IE0004445239.USD","PSIL","BK4534","LU0861579265.USD","MEDX","IE00BJT1NW94.SGD","LU0689626769.HKD","LU0708994859.HKD","LU0234570918.USD","LU0795875086.SGD","LU0310799852.SGD","LU1244550494.USD","BK4550","AGNG","LU2237443895.HKD","RXL","LU1551013342.USD","IE00B19Z3B42.SGD","VHT","BBC"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":4,"totalSize":200,"code":"91000000","status":"200"}]}}